TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07825402: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)

Sponsor: Ono Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 486 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT07825402 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07825402 Rescue Dossier →